Interleukin 2 in cancer therapy

G. K. Antony, Arkadiusz Z Dudek

Research output: Contribution to journalArticlepeer-review

74 Scopus citations


Cancer immunotherapy with interleukin-2 (IL-2) has demonstrated long term disease control in metastatic renal cell carcinoma and malignant melanoma. With introduction of novel kinase inhibitors, immunomodulatory molecules, cytokines, and vaccines for treatment of cancer there is an increased interest in combining these therapeutic strategies with IL-2. Here we discuss toxicity and established activity of IL-2 in the management of advanced malignancies, and speculate on future use of this cytokine for treatment of cancer.

Original languageEnglish (US)
Pages (from-to)3297-3302
Number of pages6
JournalCurrent Medicinal Chemistry
Issue number29
StatePublished - Oct 21 2010


  • Immunotherapy
  • Interleukin-2
  • Kidney cancer
  • Melanoma


Dive into the research topics of 'Interleukin 2 in cancer therapy'. Together they form a unique fingerprint.

Cite this